NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD
59.08
-1.56 (-2.57%)
The current stock price of ANIP is 59.08 USD. In the past month the price decreased by -13.59%. In the past year, price decreased by -3.65%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 52.69 | 687.25B | ||
JNJ | JOHNSON & JOHNSON | 15.24 | 368.56B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 19.49 | 302.74B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.57 | 222.75B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.73 | 216.03B | ||
MRK | MERCK & CO. INC. | 9.88 | 193.71B | ||
PFE | PFIZER INC | 7.18 | 130.67B | ||
SNY | SANOFI-ADR | 13.78 | 129.50B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.4 | 95.65B | ||
GSK | GSK PLC-SPON ADR | 6.99 | 77.98B | ||
ZTS | ZOETIS INC | 26.82 | 72.01B | ||
HLN | HALEON PLC-ADR | 22.65 | 50.05B |
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI PHARMACEUTICALS INC
210 Main Street West
Baudette MINNESOTA 56623 US
CEO: Nikhil Lalwani
Employees: 897
Phone: 12186343500
The current stock price of ANIP is 59.08 USD. The price decreased by -2.57% in the last trading session.
The exchange symbol of ANI PHARMACEUTICALS INC is ANIP and it is listed on the Nasdaq exchange.
ANIP stock is listed on the Nasdaq exchange.
14 analysts have analysed ANIP and the average price target is 83.06 USD. This implies a price increase of 40.58% is expected in the next year compared to the current price of 59.08. Check the ANI PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of 1.27B USD. This makes ANIP a Small Cap stock.
ANI PHARMACEUTICALS INC (ANIP) currently has 897 employees.
ANI PHARMACEUTICALS INC (ANIP) has a support level at 56.17 and a resistance level at 60.65. Check the full technical report for a detailed analysis of ANIP support and resistance levels.
The Revenue of ANI PHARMACEUTICALS INC (ANIP) is expected to grow by 30.55% in the next year. Check the estimates tab for more information on the ANIP EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANIP does not pay a dividend.
ANI PHARMACEUTICALS INC (ANIP) will report earnings on 2025-08-04, before the market open.
The PE ratio for ANI PHARMACEUTICALS INC (ANIP) is 10.38. This is based on the reported non-GAAP earnings per share of 5.69 and the current share price of 59.08 USD. Check the full fundamental report for a full analysis of the valuation metrics for ANIP.
The outstanding short interest for ANI PHARMACEUTICALS INC (ANIP) is 11.11% of its float. Check the ownership tab for more information on the ANIP short interest.
ChartMill assigns a technical rating of 1 / 10 to ANIP. When comparing the yearly performance of all stocks, ANIP turns out to be only a medium performer in the overall market: it outperformed 49.1% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to ANIP. ANIP has an average financial health and profitability rating.
Over the last trailing twelve months ANIP reported a non-GAAP Earnings per Share(EPS) of 5.69. The EPS increased by 19.54% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -0.5% | ||
ROE | -1.45% | ||
Debt/Equity | 1.38 |
ChartMill assigns a Buy % Consensus number of 84% to ANIP. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 26.64% and a revenue growth 30.55% for ANIP